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Objective: To identify the differential expression of candidate gluconeogenic genes
which may initiate hepatitis C virus (HCV) related metabolic disorder during early stages
of disease.
Methods: Patients of diverse age and sex, with positive HCV genotype 3 (HCV-3) RNA
in serum and with no history of other related infections, co-infections, alcoholism, dia-
betes or chemotherapeutic treatments were considered for this study. Semi-quantitative
reverse transcriptase PCR analysis and quantitative fold change analysis of the fresh
liver biopsies of eight chronically infected HCV-3 patients and six healthy individuals
were evaluated for three potential biomarkers involved in glucose homeostasis induction,
namely mitochondrial phosphoenolpyruvate carboxykinase 2 (PCK2), glucose-6-
phosphatase catalytic subunit (G6PC) and associated forkhead box protein 01 (FOXO1).
Results: Symptomatic evaluation, clinical history and blood test were conducted ac-
cording to general disease prognosis procedures and reported here. Signiﬁcantly upre-
gulated expression of PCK2 independent of age, sex and viral infectivity levels in all
HCV patients was observed, whereas no signiﬁcant changes in the expression of G6PC
and FOXO1 were found.
Conclusions: PCK2 triggers initial gluconeogenic reactions which ultimately result in
the accumulation of glycogen in the liver hepatocytes. We therefore suggest that the
overproduction of PCK2 has important physiological role in the onset of metabolic
disorder in the HCV-3 patients.1. Introduction
Approximately, 170 to 200 million people are infected with
hepatitis C virus (HCV) worldwide, which is about 3.3% of the
world's population [1,2]. Infection with HCV is associated with
an increased risk of fatty liver disease, diabetes type-2 (DT2)
and a condition referred to as non-alcoholic steatohepatitis
(NASH) [3]. Fatty liver disease is a state in which abnormal
retention of massive vacuoles of triglyceride fat and glycogen
accumulates in liver cells through the process of steatosis.NASH is a chronic liver condition in which both fatty liver
disease and DT2 are present but other causes of fat
accumulation, such as alcohol abuse, autoimmune hepatitis,
alpha-1 antitrypsin deﬁciency, corticosteroids and estrogens
use are absent [4]. In Pakistan, more than 10 million people are
assumed to be infected with HCV and the most prevalent
genotype is 3 [5]. Among all HCV genotypes, genotype 3 has
more signiﬁcant association with accelerated ﬁbrosis
comparatively [6]. Insulin resistance and DT2 can adversely
affect HCV infected patients by reducing SVR and accelerate
disease progression [3,7]. In addition to that, sustained
virological response is one of the major causes of HCV
associated steatosis and an increased risk of hepatocellular
carcinoma [7,8]. Furthermore, higher incidence of transplant-
related morbidity and mortality is observed in patients with in-
sulin resistance and DT2 [9].pen access article under the CC BY-NC-ND
Table 1
History and clinical diagnostic data of all enrolled subjects (HCV+ and HCV− control).
Sample
name
Age
(yrs)
Sex ALT
U/L
Viral load
(copy/mL)
Symptoms description Blood
glucose
levels
Histopathological
abnormalities
Abdominal
ultrasound
HCP1 47 F 86 290000 No hepatitis C symptoms and general health issuesd Normala Not-NASHb Normalc
HCP2 32 M 79 350000 Few hepatitis C symptoms such as dizziness and body ached Normala Not-NASHb Normalc
HCP3 38 F 65 605000 No hepatitis C symptoms and general health issuesd Normala Not-NASHb Normalc
HCP4 35 M 29 84930 No hepatitis C symptoms and general health issuesd Normala Not-NASHb Normalc
HCP5 29 M 69 336841 Few hepatitis C symptoms such as dizziness and weaknessd Normala Not-NASHb Normalc
HCP6 16 M 117 147000 No hepatitis C symptoms and general health issuesd Normala Not-NASHb Normalc
HCP7 36 F 53 220000 No hepatitis C symptoms and general health issuesd Normala Not-NASHb Normalc
HCP8 45 F 62 228689 Few hepatitis C symptoms such as dizziness and body ached Normala Not-NASHb Normalc
a Fasting and post-prandial blood glucose levels <7 mmol/L and <9 mmol/L respectively, were considered as ‘Normal’.
b All biopsies were scored <3 as described elsewhere [19] and were diagnosed as not nonalcoholic steatohepatitis or ‘not NASH’.
c
‘Normal’ in parenchymal echotexture with no intra-hepatic or extra-hepatic cholestasis and no focal lesions.
d Detailed description of hepatitis C symptoms is described in the introduction section.
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gluconeogenesis has been extensively described [10,11].
Microarray analysis of HCV infected subjects (in particular
genotype 3) has shown the induced transcription of several
metabolic genes in the liver tissues [3,6]. Expression levels of
hepatic phosphoenolpyruvate carboxykinase (PCK) which is
an important gluconeogenesis enzyme, greatly inﬂuences the
modulation of glucose synthesis [11]. Mitochondrial PCK is
encoded by the PCK2 gene located at 14q11.2 chromosome in
humans. A cytosolic form of this protein is encoded by a
different gene, PCK1, which has received the most attention
due to its higher expression in mouse liver, but in humans
both isozymes are expressed approximately equally [12]. G6PC
catalyzes the hydrolysis of D-glucose 6-phosphate to D-glucose
and orthophosphate and is a key functioning enzyme involved in
gluconeogenesis and glycogenolysis. Forkhead box O1
(FOXO1) is a transcription factor responsible for the regulation
of PCK and glucose-6-phosphatase, catalytic subunit (G6PC)
gene expression. Mis-regulated expression of hepatic PCK,
G6PC and FOXO1 in HCV infected hepatocellular carcinoma
cell lines (namely huh7.5 and huh.8) have shown a
direct involvement of the HCV core and nonstructural 5A
protein [10,11,13,14]. Higher expression levels of PCK, G6PC and
FOXO1 mRNA in the liver biopsies of HCV patients with
steatosis were observed when compared with normal liver
hepatocytes [15].
Clinical symptoms of HCV infection such as fatigue, joint
pain, belly pain, itchy skin, sore muscles and dark urine, onlyFigure 1. Semi-quantitative results of RT-PCR, illustrating relative gene expre
Lane 1 100 bp ladder, Lane 2, 3, 4, 5, 6, 7, 8, 9 showing 104 bp PCK2 ex
respectively. Lane 10–15 showing 104 bp PCK2 expression levels of normal
GAPDH as endogenous control.develop in minority of cases. This paucity of symptom keeps
most cases undiagnosed even after many years of HCV
infection [16]. As the association of HCV infection and DT2 is
present before the onset of cirrhosis, here we aimed to
evaluate the expression of PCK2, G6PC and FOXO1 as
potential biomarkers to induce HCV associated glucose
homeostasis and associated metabolic liver disorders.
2. Materials and methods
2.1. Patient(s) characteristics
All patients were enrolled for sampling according to the
ethical guidelines of the 1975 Declaration of Helsinki after
approval of hospital ethic committee. The routine histopatho-
logical test was ordered by the patient's physician
after explaining the risks and beneﬁts of testing to the patient
and had obtained written informed consent. A recent clinic
note summarizing the case and the prior workup was also
provided by the patient's physician. A short clinical ques-
tionnaire was constructed to collect the patients' history by
interview. Subjects of varying gender and age were enrolled.
As our aim was to look at the expression levels exclusively due
to HCV replication, we adopted stringent enrollment criteria
and only those patients who met the following conditions were
enrolled: 1) chronically infected HCV patients of diverse
age, sex (male/female) with positive viral RNA in serum; 2)
No other known viral and/or bacterial co-infection, alcoholismssion pattern of PCK2 in all HCV+ Subjects vs. HCV− controls.
pression levels of HCP1, HCP2, HCP3, HCP4, HCP6, HCP7 and HCP8
control sample NC1 to NC6 (Table 2). All samples were normalized with
Table 2
Detailed speciﬁcations of oligos.
Srl. No. Target gene name and accession number Primer sequence 50-30 Amplicon size
1 Homo sapiens FOXO1 mRNA NM_002015 Left-CGCCCTCGAACTAGCTCAAA
Right-GCGGGTACACCATAGAATGCA
109 bp
2 Homo sapiens PCK2 mRNA NM_001018073 Left-CAAGACCAACCTGGCTATGATG0
Right-GGAGTCGACCTTCACTGTCAAAC
104 bp
3 Homo sapiens G6PC mRNA NM_000151 Left-AGTTGTTGCTGGAGTCCTGTCA
Right-GGTCTACACCCAGTCCCTTGAG30
161 bp
4 Homo sapiens GAPDH mRNA NM_002046 Left-AGGGGCCATCCACAGTCTTC
Right-AGAAGGCTGGGGCTCATTTG
258 bp
Figure 2. Quantitative RT-PCR analysis of PCK2, G6PC, and FOXO1
relative fold changes in the gene expression of individual HCV+ subject
were calculated using DDCt method.
All Ct (cycle threshold) values were normalized to an endogenous reference
gene (GAPDH) and shown after log transformation. (2a) PCK2 (2b) G6PC
and (2c) FOXO1 relative to gene expression in HCV negative control
subjects is shown in each graph. Error bars indicate S.E.M. *P < 0.05,
**P < 0.001, ***P < 0.0001.
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and/or interferon, pegylated interferon and ribavirin therapy
treatment history. Postmortem liver samples of healthy
individuals with negative HCV viral RNA (RT-PCR) and 40
alanine transaminase (ALT) levels with no apparent liver
abnormalities were taken as HCV negative controls
(First Choice® Human Tissue Total RNA Ambion®, Life
Technologies™ USA). Blood tests such as HCV viral load
(copies/mL) and HCV genotyping were conducted at the Na-
tional University of Science and Technology's molecular
diagnostic facility as recommended by center for disease
control USA (http://www.cdc.gov/hepatitis/HCV/GuidelinesC.
htm).
2.2. Sample collection
The sampling was done at PIMS Islamabad, following
approval by the Hospital Ethics Committee. Written informed
consent was obtained from the patients for publication of this
report. Two milliliter whole blood samples were collected in a
sterile blood collection tube for histological evaluation and
partly for RNA extraction. The surgically removed biopsy
samples were processed for routine histopathological examina-
tion. The sample part unnecessary for histological diagnosis was
placed in RNAlater (Ambion®, Life Technologies™ USA) for
gene expression studies. The negative control sample was pre-
pared from the tissues that had been frozen and stored in
RNAlater. All samples were placed at −80 C.
2.3. Clinical diagnostics
Blood samples from each subject were used to conduct
clinical diagnostic assessments including complete blood pic-
ture, blood glucose and ALT levels, HCV Genotyping and viral
load quantiﬁcation (Table 1). Each patient was examined for
histopathological abnormalities and by abdominal ultrasound for
visible change in liver echotexture.
2.4. RNA preparation
Total RNA of all tissue samples was extracted by using
RNAqueous®-4PCR Kit (Ambion®, Life Technologies™ USA)
according to manufacturer's instructions. Total RNA prepared
from normal liver tissues that had been frozen/stored in RNA-
later before extraction were used as an HCV negative control.
Final concentrations of all the RNA samples including HCV
negative healthy control were adjusted to 50 ng/mL by using
260/280-nm absorbance ratio (BioPhotometer Plus &Hellma®
Tray Cell, Eppendorf).2.5. Reverse transcriptase quantitative real time
polymerase chain reaction (qRT-PCR)
Primers for PCK2, G6PC and FOXO1 were designed with
the assistance of the Primer Express 3.0 software (Applied
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RevertAid™ First Strand cDNA Synthesis Kit by using random
hexamer primers (All from Fermentas) were then ampliﬁed by
using oligos targeting transcripts of PCK2, G6PC and FOXO1.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used with all cDNA samples as an endogenous control.
qRT-PCR of ﬁrst stand cDNA of three replicates of each
sample targeting transcripts of PCK2, G6PC and FOXO1 were
performed on 7300 Fast Real-Time PCR Systems (Applied
Biosystems USA). 50 mL reactions with Taq Polymerase with
optimal 5× Taq buffers, 2 mM dNTPs mix and 25 mM MgCl2
(All from Fermentas) were prepared. Forty cycles of ampliﬁca-
tion at 95 C for 30 s (denaturation), 55 C for 30 s (annealing)
followed by 72 C for 60 s (extension) were used to measure the
ﬂuorescence signal. Reaction concentrations and conditions
were adjusted according to the manual instructions of Platinum®
SYBR® Green QPCR Super Mix UDG (Invitrogen, U.S.A).
Equal quantities of cDNA from normal patients were taken as a
negative control. All samples were normalized with reference
genes (GAPDH). Five microliter PCR products along with
control samples and 100 bp ladder (Fermentas) were electro-
phoresed in ethidium bromide stained 2% agarose gel and
resolved using a gel documentation system (Wealtec Dolphin
USA). GAPDH PCR products were also electrophoresed to
determine PCR efﬁciency.
2.6. Data analysis
Quantitative analyses of the data were carried out using 7300
system SDS software v1.4 (Applied Biosystems, USA) and >35
cycle threshold (Ct) value, out of 40 cycles of ampliﬁcation were
considered as un-detected [17]. Fold difference in gene
expression was calculated by using a comparative method
(DDCt method) [18]. Statistical differences (mean DCt values,
SDV and SEM) were analyzed using Microsoft Excel. SEM is
indicated in error bars. The descriptive statistical data analysisFigure 3. Model representation of initial stages of fatty live disease and hype
Color codes representing low (green), normal (black) and high (red) expression
FOXO1) involved in the important pathways of glucose metabolism. Changes
pathways in the liver hepetocytes which may lead to metabolic disorder in thewas calculated using Microsoft Excel and P values were
calculated using two tailed Student's t-test for statistical
signiﬁcance.
3. Results
3.1. Patients' details
Patients' details and reports of all clinical tests conducted for
the study are summarized in Table 1.
3.2. Hepatic expression of PCK2, G6PC and FOXO1
Our semi-quantitative analysis showed dramatic upregulation
of PCK2 transcriptional expression in eight chronically infected
HCV genotype 3 (CHV3) subjects in comparison with six
normal controls but no noticeable or consistent differences were
observed between both groups for G6PC and FOXO1 expres-
sion (Figure 1 & Table 2 for amplicon size). The band intensity
analysis revealed that, although these expression levels are
signiﬁcantly different between both groups, they also vary
among CHV3 patients. To describe the risk intensity of devel-
oping DT2 in individual patients, the differences in expression
were further quantiﬁed with qPCR in separate experiments
(Figure 1). Due to low RNA yield from liver biopsies we could
not precede with two CHV3 patients (HCP7 and HCP8) for
further fold change analysis.
Six CHV3 samples were evaluated with quantitative fold
change analysis and compared with two normal controls.
GAPDH normalized expression of PCK2, G6PC and FOXO1 in
HCP1 was ~7.78, ~1.58 and ~3.27 fold, respectively. For HCP2
GAPDH normalized expression of PCK2, G6PC and FOXO1
was ~9.71, ~1.69 and ~1.07 fold, respectively (Figure 2). For
HCP3 the GAPDH normalized expression of PCK2, G6PC and
FOXO1 was ~15.77, ~1.04 and ~1.1 folds, respectively. For
HCP4 the GAPDH normalized expression of PCK2, G6PC andrglycemia development in the HCV infected liver hepatic cells.
of metabolic genes of enzymes and transcription factor (PCK2, G6PC and
in these gene expressions may result in the dysregulated glucose metabolic
later stages of the disease.
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GAPDH normalized expression of PCK2, G6PC and FOXO1
was ~38.05, ~1.68, ~2.17 fold, respectively and for HCP6 the
GAPDH normalized expression of PCK2, G6PC and FOXO1
was ~20.24, ~4.19, ~1.95 fold respectively (Figure 2). Based on
these results we have suggested a hypothetical model of
glycogen accumulation in the liver which ultimately results in
the development of fatty liver disease in the HCV infected pa-
tients (Figure 3).
To exclude the possible effects of other factors such as
gender, HCV viral load and age in the development of glucose
homeostasis, correlation analysis of PCK2, G6PC and FOXO1
gene expression was done. No correlations were found among
HCV infected patients, between altered gene expression of
PCK2, FOXO1 and G6PC with gender and HCV viral load
(Data not shown).
4. Discussion
HCV nonstructural proteins interact with gluconeogenic en-
zymes (PCK, G6Pases) and associated transcription factors
(FOXO1) and dramatically affect their gene expression regula-
tion in HCV infected hepatocellular carcinoma cells such as Huh
7.5, Huh.8. The dominant effect of FOXO1 proteins among
other transcriptional factors and cofactors such as peroxisome
proliferator-activated receptor gamma coactivator 1-alpha,
cAMP response element-binding and CCAAT enhancer-binding
proteins has recently been reported [10,11,13,14]. To our
knowledge, this is the ﬁrst study highlighting upregulated
mitochondrial PCK as an early biomarker of metabolic
disorder in the HCV-3 patients. In the normal human liver
PCK2 express with equal proportion as cytosolic PCK isozyme,
PCK1 [19]. The mitochondrial location PCK2 is crucial for initial
gluconeogenic reactions as the carboxylation of pyruvate to
oxaloacetate by pyruvate carboxylase occurs in the
mitochondrion. For cytosolic PCK, oxaloacetate needs to be
shuttled out, but for mitochondrial PCK, no shuttle of
oxaloacetate is needed [4,19]. Furthermore FOXO1 is a well
known transfection factor which induces expression G6Pases
and PCK1 [13] but its role in the regulation of PCK2 was
unknown. In our results, we found upregulated expression
PCK2 but on the other hand expression of FOXO1 was
similar in HCV patient as compared to normal control. This
therefore suggests that FOXO1 is not involved in the
expression of PCK2. Normal expression of G6PC also
conﬁrms that PCK2 mediate gluconeogenic reactions by
independent mechanisms.
In our results we observed a dramatic change in the expres-
sion of PCK2 consistently on HCV infected patients. Whereas in
the case of FOXO1 and G6Pase, this dramatic change of >3 and
4 folds was only observed in HCP1 and HCP6, respectively. All
other HCV patients showed almost similar expression of
FOXO1 and G6PCas that of normal subjects. As the upregulated
expression levels of FOXO1 and G6PC were reported in the
Huh. Cells which represent hepatic steatosis or hepatocellular
carcinoma, here we assume that these changes in the expression
may only appear in the later stage of the disease. Moreover,
HCP6 has unusual liver damage as indicated by his abnormally
high ALT levels (117 U/L) which may also have some relation
to the elevated expression of G6PC. This may also be true for
HCP1 (ALT 86 U/L). On the other hand, PCK2 showed a
consistently high expression level ranging from ~7 to 38 folds,independent of any other factor such as age, gender, HCV or
ALT. Therefore, we suggest that PCK2 triggers initial gluco-
neogenic reactions which result in the accumulation of glycogen
in the liver hepatocytes. Furthermore, functional effect of PCK2
must be considered in the future studies to study the overall
physiology of metabolic disorder associated with HCV
infection.
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